High-risk lineages among extended-spectrum β-lactamase-producing Escherichia coli from extraintestinal infections in Maputo Central Hospital, Mozambique.
Amoxicillin
Anti-Bacterial Agents
/ pharmacology
Carbapenems
Cefotaxime
Ceftazidime
Ciprofloxacin
Clavulanic Acid
Escherichia coli
Escherichia coli Infections
/ epidemiology
Escherichia coli Proteins
/ genetics
Extraintestinal Pathogenic Escherichia coli
/ genetics
Gentamicins
Hospitals
Humans
Iron
Mozambique
/ epidemiology
Piperacillin
Tazobactam
Trimethoprim, Sulfamethoxazole Drug Combination
beta-Lactamases
/ genetics
AmpC
ESBL
Escherichia coli
ExPEC
Virulence determinant
Whole-genome sequencing
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
12
01
2022
revised:
29
07
2022
accepted:
31
07
2022
pubmed:
8
8
2022
medline:
28
9
2022
entrez:
7
8
2022
Statut:
ppublish
Résumé
Extended-spectrum β-lactamase (ESBL)-producing extraintestinal pathogenic Escherichia coli (ExPEC), particularly high-risk lineages, are responsible for severe infections and increased mortality and hospital costs worldwide, with a major burden in low-income countries. Here we determined the antimicrobial susceptibility and performed whole-genome sequencing of E. coli isolates from extraintestinal infections of patients during 2017-2018 at Maputo Central Hospital (Mozambique). Multidrug resistance was displayed by 71% of isolates (17/24). All isolates resistant to cefotaxime and ceftazidime were positive for ESBL genes (16/24; 67%) and were co-resistant to amoxicillin/clavulanate (14/16; 88%), piperacillin/tazobactam (8/16; 50%), gentamicin (12/16; 75%), trimethoprim/sulfamethoxazole (15/16; 94%) and ciprofloxacin (11/16; 69%). Several major high-risk ExPEC lineages were identified, such as H30Rx-ST131, fimH41-ST131, H24Rx-ST410, ST617, ST361 and ST69 harbouring bla
Identifiants
pubmed: 35934230
pii: S0924-8579(22)00165-0
doi: 10.1016/j.ijantimicag.2022.106649
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
Escherichia coli Proteins
0
Gentamicins
0
Clavulanic Acid
23521W1S24
Ciprofloxacin
5E8K9I0O4U
Amoxicillin
804826J2HU
Trimethoprim, Sulfamethoxazole Drug Combination
8064-90-2
Ceftazidime
9M416Z9QNR
Iron
E1UOL152H7
beta-Lactamases
EC 3.5.2.6
Cefotaxime
N2GI8B1GK7
Tazobactam
SE10G96M8W
Piperacillin
X00B0D5O0E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106649Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None declared.